Skip to main content

Table 1 Training cohort: clinical characteristics of patients for immunohistochemistry experiment

From: Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors

Patients

Number (%)

Number

69

Age (years), mean (range)

61.9 (36–86)

Histology

Serous

69 (100)

Stage

I

6 (9)

II

6 (9)

III

51 (74)

IV

5 (7)

Grade

1

2 (3)

2

3 (4)

3

57 (83)

Chemotherapy

Neo-adjuvant

35 (51)

Adjuvant

32 (46)

Surgery

Not robotic

32 (46)

Robotic

35 (51)

Residual disease

4 (6)

Response

Responsive

41 (59)

Resistant

19 (28)

Recurrence

Number

41 (59)

Mean time (range)

17.9 months (3–84)

Deceased

Number

21 (30.4)

Mean time (range)

27.9 months(10–72)

Follow-up

Mean time (range)

36.6 months (7–111)